This Is MS Multiple Sclerosis Knowledge & Support Community

The folks at my study group are more than a little pissed at this stance by the Campath group and they plan to continue to pester the Campath folks about it. Hello all, I spoke with my Tovaxin research group coordinator today regarding a tizanidine prescription refill and she said that they had tal...

Hello all, I had my visit with my study doc on Thursday and as Marcia explained it was not dictated by Opexa but by my study group just to talk to me about my options. My insurance is tied to the university where I work so the visit with the study doc, which lasted ~30 minutes, was completely free o...

Hey gang,

I thought it would be interesting to have a topic where we post how the termination appointment went as well as what meds/treatment did you decide to switch to. My termination appointment is tomorrow so I will update you then.

Take care,
Mike

Morning folks,

I just received my call that it's over as well. I go in next Thursday to discuss what my options are but it will almost certainly be limited to the CRABs or Tysabri because we are not eligible to jump ship to the Campath study.

Bummer!

Mike

It just occurred to me that not only have I never done the "long walk", I don't even know what it is. Lars, At least at my study site, it's a 500 yard walk. They do time how long it takes to complete the walk but it is not required that you have to be able to complete it in any specified ...

Have you had no progression? any improvement in EDSS? Howdy all, First, I thank you for all of your nice comments on my writing ability. Describing technical issues I guess is a product of my profession. However, don't expect much if you want me to write a fluffy story! As for my progression status...

Howdy all,

I wanted to give a little update on something that has not happened to me since I've had MS! I have now gone a full year without an exacerbation! The longest I've ever gone before was 9 months.

Take care,
Mike

Opexa Provides Additional Promising Data Including Statistically Significant Reduction in Disability With Tovaxin® for the Treatment of Multiple Sclerosis Tovaxin Also Demonstrates Reduction in Relapse Risk and Myelin T-cell Reactivity in Patients With More Active Disease THE WOODLANDS, Texas--(BUSI...

I keep reading that its failure is because of "epitote shift". Is there any reason that no one is simply saying that there is a major gap in the epitotes that they are specifically looking for? Cure, The data that Opexa has presented regarding epitope shift was in Figure 3 of a poster (se...

Howdy all, I'm a few days early here but what the heck! My MS: I am 42 years old and my first MS attack was in October 2003 and the actual MS diagnosis came during my second attack in August 2004. The majority of my lesions are in my spinal cord so my symptoms are exclusively motor and sensory and m...

As long as there can be nothing but gross speculation at this point, I have to wonder if there might not be an abundance of different MS epitope relationships, but that they vary greatly in importance and that maybe, just maybe by fate or design, the original treatments were aimed at the most impor...

You don't think you're taking this a bit personally when all I did was report that Tovaxin just failed a phase II trial, which it did, and the stock went from $2.40 to $0.20 (basically zero)? Why should we take it personally when you describe the minimal information to be released from a preliminar...

As for me, my study is being closed out at the end of the year. I guess I will see how long the protective effect last So Tim, Do I understand you correctly that you will no longer have procurements and vaccinations via Opexa and that they are casting you and your study group out to sea to fend for...

Stunning results with the worst group makes for a stunning future. Backfire. Their opinion is that Tovaxin still has a future with mildly affected patients but NOT with advanced cases. Lars, That is an interesting interpretation and one that could easily be flipped 180° with the interpretation that...

Opexa went to great lengths to highlight the fact that there was "over 90 % reduction" in the first phases. I can assure you that is how they achieved funding and willing recruits. I can also assure you that if there were any way to make that case now.....they would have. Lars, Yes, Opexa...